Browsing Tag
National Medical Products Administration
23 posts
Akeso gumokimab approval strengthens China biologics push as psoriasis market heats up
Find out how Akeso’s gumokimab approval could reshape China’s psoriasis biologics market and boost its autoimmune drug strategy.
Can Kelun-Biotech and Merck turn sac-TMT into the first ADC plus immunotherapy standard in front-line lung cancer?
Merck needs life after Keytruda. Kelun-Biotech’s sac-TMT lung cancer data may show how the next oncology cycle takes shape.
Biogen (BIIB) buys felzartamab rights in China from TJ Biopharma for up to $850m, completing global ownership
Biogen pays $100M upfront for felzartamab's China rights from TJ Biopharma, completing global ownership of the CD38 antibody with up to $850M at stake. Read the full analysis.
Why BeOne Medicines (ONC) just strengthened its China oncology play with Imdelltra approval
BeOne Medicines wins China approval for Amgen’s Imdelltra in lung cancer. Read why this matters for ONC, competition, and China oncology growth.
Could subcutaneous PD-1 therapy reshape oncology treatment logistics in China?
Could subcutaneous PD-1 therapy reshape cancer treatment in China? Explore Junshi Biosciences’ toripalimab filing and its impact on oncology logistics.
Akeso secures fifth NMPA breakthrough therapy designation for ivonescimab, sharpening its first-line oncology ambitions in China
Akeso Inc. secures a fifth breakthrough therapy designation for ivonescimab. Find out why this matters for oncology strategy and investors.
GSK wins approval in China for Nucala in eosinophilic COPD, expanding respiratory biologics reach
Find out how GSK’s Nucala just became the first biologic approved for eosinophilic COPD in China—and what it means for the future of respiratory care.
Innovent Biologics secures FDA greenlight for first global Phase 3 trial of IBI363 in lung cancer
Innovent Biologics wins FDA approval for its first global Phase 3 trial of IBI363 in lung cancer, signaling a major milestone in immuno-oncology.
Zai Lab stock rallies on regulatory optimism in China’s oncology sector
Zai Lab stock jumps 7.6% on China FDA review optimism for its oncology drugs, as cross-border biotech sentiment improves. Read the full investor analysis.
Innovent’s IBI363 gains NMPA breakthrough therapy designation, boosting regulatory momentum
Innovent’s IBI363 secures NMPA breakthrough therapy designation for melanoma. Discover its clinical potential, investment outlook, and global impact.